GC promotes the conversion of human monocytes to CD163+ macrophages in vitro [32]. We therefore investigated the effect of GC treatment of LN on glomerular accumulation of CD163+ macrophages and u-sCD163 excretion. The number of glomerular CD163+ macrophages and u-sCD163 level were comparable between GC-treated and untreated populations in patients presenting class IV lesions (Table 3). Moreover, there was no association between GC dosage and CD163-related LN parameters (Supplementary data, Figure S2).
Clinical and laboratory data of class IV LN patients with or without GC treatment
| . | Non-GC . | GC . |
|---|---|---|
| Number of patients | 17 | 21 |
| Age (years) | 48.8 ± 17.3 | 40.7 ± 16.0 |
| Sex (male:female) | 3:14 | 2:19 |
| Dosage of GC (mg/day) | 0 | 36.2 ± 20.7 |
| Serum creatinine (mg/dL) | 1.26 ± 0.99 | 1.40 ± 1.45 |
| eGFR (mL/min/1.73 m2) | 53.7 ± 21.1 | 66.5 ± 39.3 |
| Proteinuria (g/gCr) | 5.09 ± 3.85 | 6.15 ± 4.53 |
| C3 (mg/dL) | 35.3 ± 16.0 | 42.8 ± 16.6 |
| Anti-DNA antibody (IU/mL) | 158.0 ± 131.0 | 134.3 ± 166.5 |
| CRP (mg/dL) | 0.41 ± 0.68 | 0.96 ± 1.27 |
| Total SLEDAI | 16.1 ± 4.80 | 16.6 ± 5.20 |
| Renal SLEDAI | 10.0 ± 3.30 | 10.1 ± 3.50 |
| Activity index | 7.47 ± 2.92 | 7.24 ± 2.62 |
| u-sCD163/u-Cr (ng/mg) | 50.4 ± 48.3 | 43.9 ± 39.2 |
| u-sCD163/u-TP (ng/mg) | 12.6 ± 7.40 | 12.2 ± 9.50 |
| CD163+ cells/glomerulusa | 13.6 ± 5.20 | 14.5 ± 6.60 |
| . | Non-GC . | GC . |
|---|---|---|
| Number of patients | 17 | 21 |
| Age (years) | 48.8 ± 17.3 | 40.7 ± 16.0 |
| Sex (male:female) | 3:14 | 2:19 |
| Dosage of GC (mg/day) | 0 | 36.2 ± 20.7 |
| Serum creatinine (mg/dL) | 1.26 ± 0.99 | 1.40 ± 1.45 |
| eGFR (mL/min/1.73 m2) | 53.7 ± 21.1 | 66.5 ± 39.3 |
| Proteinuria (g/gCr) | 5.09 ± 3.85 | 6.15 ± 4.53 |
| C3 (mg/dL) | 35.3 ± 16.0 | 42.8 ± 16.6 |
| Anti-DNA antibody (IU/mL) | 158.0 ± 131.0 | 134.3 ± 166.5 |
| CRP (mg/dL) | 0.41 ± 0.68 | 0.96 ± 1.27 |
| Total SLEDAI | 16.1 ± 4.80 | 16.6 ± 5.20 |
| Renal SLEDAI | 10.0 ± 3.30 | 10.1 ± 3.50 |
| Activity index | 7.47 ± 2.92 | 7.24 ± 2.62 |
| u-sCD163/u-Cr (ng/mg) | 50.4 ± 48.3 | 43.9 ± 39.2 |
| u-sCD163/u-TP (ng/mg) | 12.6 ± 7.40 | 12.2 ± 9.50 |
| CD163+ cells/glomerulusa | 13.6 ± 5.20 | 14.5 ± 6.60 |
CRP, C-reactive protein; SLEDAI, systemic lupus erythematosus disease activity index.
Data are expressed as the mean ± SD. None of the parameters showed a significant difference.
Two patients receiving GC pulse therapy (>500 mg/day) at the time of sample collection were excluded.
aKidney samples from 13 patients in the non-GC group and 16 in the GC group were evaluated.
Clinical and laboratory data of class IV LN patients with or without GC treatment
| . | Non-GC . | GC . |
|---|---|---|
| Number of patients | 17 | 21 |
| Age (years) | 48.8 ± 17.3 | 40.7 ± 16.0 |
| Sex (male:female) | 3:14 | 2:19 |
| Dosage of GC (mg/day) | 0 | 36.2 ± 20.7 |
| Serum creatinine (mg/dL) | 1.26 ± 0.99 | 1.40 ± 1.45 |
| eGFR (mL/min/1.73 m2) | 53.7 ± 21.1 | 66.5 ± 39.3 |
| Proteinuria (g/gCr) | 5.09 ± 3.85 | 6.15 ± 4.53 |
| C3 (mg/dL) | 35.3 ± 16.0 | 42.8 ± 16.6 |
| Anti-DNA antibody (IU/mL) | 158.0 ± 131.0 | 134.3 ± 166.5 |
| CRP (mg/dL) | 0.41 ± 0.68 | 0.96 ± 1.27 |
| Total SLEDAI | 16.1 ± 4.80 | 16.6 ± 5.20 |
| Renal SLEDAI | 10.0 ± 3.30 | 10.1 ± 3.50 |
| Activity index | 7.47 ± 2.92 | 7.24 ± 2.62 |
| u-sCD163/u-Cr (ng/mg) | 50.4 ± 48.3 | 43.9 ± 39.2 |
| u-sCD163/u-TP (ng/mg) | 12.6 ± 7.40 | 12.2 ± 9.50 |
| CD163+ cells/glomerulusa | 13.6 ± 5.20 | 14.5 ± 6.60 |
| . | Non-GC . | GC . |
|---|---|---|
| Number of patients | 17 | 21 |
| Age (years) | 48.8 ± 17.3 | 40.7 ± 16.0 |
| Sex (male:female) | 3:14 | 2:19 |
| Dosage of GC (mg/day) | 0 | 36.2 ± 20.7 |
| Serum creatinine (mg/dL) | 1.26 ± 0.99 | 1.40 ± 1.45 |
| eGFR (mL/min/1.73 m2) | 53.7 ± 21.1 | 66.5 ± 39.3 |
| Proteinuria (g/gCr) | 5.09 ± 3.85 | 6.15 ± 4.53 |
| C3 (mg/dL) | 35.3 ± 16.0 | 42.8 ± 16.6 |
| Anti-DNA antibody (IU/mL) | 158.0 ± 131.0 | 134.3 ± 166.5 |
| CRP (mg/dL) | 0.41 ± 0.68 | 0.96 ± 1.27 |
| Total SLEDAI | 16.1 ± 4.80 | 16.6 ± 5.20 |
| Renal SLEDAI | 10.0 ± 3.30 | 10.1 ± 3.50 |
| Activity index | 7.47 ± 2.92 | 7.24 ± 2.62 |
| u-sCD163/u-Cr (ng/mg) | 50.4 ± 48.3 | 43.9 ± 39.2 |
| u-sCD163/u-TP (ng/mg) | 12.6 ± 7.40 | 12.2 ± 9.50 |
| CD163+ cells/glomerulusa | 13.6 ± 5.20 | 14.5 ± 6.60 |
CRP, C-reactive protein; SLEDAI, systemic lupus erythematosus disease activity index.
Data are expressed as the mean ± SD. None of the parameters showed a significant difference.
Two patients receiving GC pulse therapy (>500 mg/day) at the time of sample collection were excluded.
aKidney samples from 13 patients in the non-GC group and 16 in the GC group were evaluated.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
